This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Journal of Cardiovascular Electrophysiology
MARCH 10, 2025
It highlights the confluence of two major cardiovascular epidemics, atrial fibrillation and heart failure, with preserved ejection fraction. ABSTRACT This state-of-the-art review is based on the Philippe Coumel Lecture in 2024 (Figure 1).
JAMA Cardiology
MARCH 28, 2025
This secondary analysis of the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure (FINEARTS-HF) randomized clinical trial examines the efficacy and safety of finerenone in patients with heart failure with mildly reduced or preserved ejection fraction according to the presence and type of atrial fibrillation. (..)
Heart BMJ
MARCH 26, 2025
Background Heart failure with preserved ejection fraction is a recognised outcome in patients with myocardial infarction, although heart failure with reduced ejection fraction is more common. fold higher risk of heart failure with preserved ejection fraction (95% CI 1.30 m/s had a 2.10-fold
JAMA Cardiology
APRIL 23, 2024
This systematic review and meta-analysis investigates the efficacy of catheter ablation compared with rate or rhythm control among patients with atrial fibrillation and heart failure.
Frontiers in Cardiovascular Medicine
NOVEMBER 17, 2024
Multivariate linear regression analysis shows that the degree of anemia, atrial fibrillation, and TR were independently associated with the TAPSE/PASP ratio.ConclusionAnemia in HFpEF is associated with RV dysfunction, and this relationship is not affected by classical risk factors, such as smoking, hypertension, and diabetes.
HeartRhythm
OCTOBER 21, 2024
Clinical outcomes among patients with atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) treated with catheter ablation (CA) versus antiarrhythmic therapy (AAT) are not well-known.
HeartRhythm
MARCH 31, 2025
Roughly half of patients with heart failure (HF) have preserved ejection fraction (HFpEF). HFpEF and atrial fibrillation (AF) often coexist and share similar risk factors.
HeartRhythm
MARCH 31, 2025
Heart failure with preserved ejection fraction (HFpEF) is prevalent but under-recognised in patients with atrial fibrillation (AF). Existing HFpEF risk scores have suboptimal discrimination in this cohort.
Frontiers in Cardiovascular Medicine
JANUARY 28, 2024
Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) have emerged as major age-related epidemics within cardiology.
American College of Cardiology
FEBRUARY 23, 2024
What is the prevalence of subclinical atrial fibrillation (AF) in patients with heart failure and preserved ejection fraction (HFpEF), and how does it impact outcomes?
American College of Cardiology
APRIL 18, 2025
Patients who undergo catheter ablation for atrial fibrillation (AFib) who also have heart failure with preserved ejection fraction (HFpEF) experienced a greater benefit from ablation in terms of clinical outcome, AFib recurrence and functional status, according to findings from the CABANA trial.
Heart BMJ
MARCH 26, 2025
1 Left ventricular ejection fraction (LVEF) is a crucial parameter in HF assessment and management, although the differences in mortality are little different between HF with LVEF≥50% or HF with preserved ejection fraction (HFpEF) in patients with post-MI compared with HF with LVEF≤40% or HF with reduced ejection fraction (HFrEF).
HeartRhythm
MARCH 31, 2025
Studies have shown detrimental effects of atrial fibrillation (AF) occurrence among patients with heart failure (HF) with a preserved ejection fraction (HFpEF). Ablative therapy may counter this risk, but the impact of timing of ablation in paroxysmal vs. persistent AF is unclear.
HeartRhythm
APRIL 30, 2024
The efficacy of catheter ablation as a treatment approach for patients with concurrent atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) has been inadequately investigated.
Journal of the American Heart Association
APRIL 16, 2025
BackgroundAortic stenosis can lead to cardiac adaptations and symptoms similar to heart failure with preserved ejection fraction. Journal of the American Heart Association, Ahead of Print. Methods and ResultsThis retrospective cohort study included 469 patients with moderate aortic stenosis.
HeartRhythm
MARCH 31, 2025
Atrial fibrillation (AF) is a common cause of embolic stroke and strongly associated with the development of heart failure with preserved ejection fraction (HFpEF). Left atrial disease is commonly considered as central to the pathophysiology of these conditions.
HeartRhythm
JANUARY 6, 2025
Atrial fibrillation (AF) is a common arrhythmia in patients with heart failure (HF). Catheter ablation of AF has been proven to be an effective therapeutic option for AF management in HF, particularly in heart failure with reduced ejection fraction (HFrEF) [2, 3].
HeartRhythm
SEPTEMBER 4, 2024
Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) are comorbid conditions that are increasingly prevalent and have a high socioeconomic burden. This article discusses their shared pathophysiology, focusing on the triad of hypertension, obesity, and aging.We
HeartRhythm
SEPTEMBER 25, 2024
The HFA–PEFF score comprising echocardiographic and laboratory data is designed to diagnose heart failure with preserved ejection fraction and holds prognostic value in patients who underwent catheter ablation for atrial fibrillation (AF).
HeartRhythm
APRIL 30, 2024
Studies have suggested that early atrial fibrillation (AF) ablation is associated with improved outcomes. However, it is unknown whether these patterns hold for persistent AF among patients with heart failure with preserved ejection fraction (HFpEF). The majority of these studies evaluated paroxysmal AF cases.
HeartRhythm
APRIL 14, 2024
The benefit of catheter ablation in patients with atrial fibrillation (AF) for patients with heart failure with preserved ejection fraction (HFpEF) remains uncertain.
HeartRhythm
APRIL 30, 2024
Left atrial and pulmonary artery pressure (PAP) elevation can reflect severity and dynamic status of heart failure (HF) in HF with preserved ejection fraction (pEF). Atrial fibrillation (AF) worsens HFpEF progression and pump failure, but catheter ablation can restore rhythm control in this population.
DAIC
JUNE 4, 2024
Late-breaking Clinical Trial Results from FARADISE, admIRE Study and Advent Trial at Heart Rhythm 2024 Highlight Pulsed Field Ablation Developments for Atrial Fibrillation Treatment 8. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) 10.
American College of Cardiology
MARCH 21, 2024
What is the utility and validity of HFA-PEFF and H2FPEF scores for diagnosis of heart failure with preserved ejection fraction (HFpEF) in patients with symptomatic atrial fibrillation (AF)?
Journal of Cardiovascular Electrophysiology
DECEMBER 17, 2024
Abstract Background Heart failure (HF) with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) are associated with high morbidity and mortality. However, it remains unclear whether SRM after a repeat CA for recurrent AF has the same effect as SRM after the initial CA in patients with AF and HFpEF.
Frontiers in Cardiovascular Medicine
FEBRUARY 8, 2024
This study investigates the utility of echocardiographic left ventricular (LV) to left atrial (LA) volume ratio in estimating the resting FP in patients with dyspnoea and preserved ejection fraction (EF). For patients in sinus rhythm specifically, the cut-off value was ≤1.28 (AUC = 0.799), with P < 0.0001 for both.
HeartRhythm
APRIL 30, 2024
The data on comparison of parameters of diastolic dysfunction (DD) on transthoracic echocardiogram (TTE) according to the progressive stages of AF in patients with coexisting heart failure with preserved ejection fraction (HFpEF) are limited.
Circulation
JANUARY 22, 2025
Optimal NT-proBNP cut points for HFpEF rule out (optimizing sensitivity) and rule in (optimizing specificity) were derived and tested, stratified by obesity and atrial fibrillation. Circulation, Ahead of Print.
DAIC
JULY 31, 2024
mtaschetta-millane Wed, 07/31/2024 - 06:00 July 31, 2024 — A novel study co-authored by a heart failure cardiologist at University Hospitals Harrington Heart & Vascular Institute, demonstrates the effectiveness of a newly developed scoring system in identifying patients with Heart Failure with Preserved Ejection Fraction (HFpEF).
111 
HeartRhythm
MARCH 31, 2025
Cardiorespiratory fitness is a modifiable risk factor associated with the development and progression of atrial fibrillation. However, whether a smaller left ventricular (LV) volume is associated with reduced CRF in individuals with atrial fibrillation (AF) has not been well established.
HeartRhythm
MARCH 31, 2025
While there are several reports on the efficacy of catheter ablation for atrial fibrillation (AF) in patients with heart failure with preserved ejection fraction (HFpEF), comprehensive data on the optimal catheter ablation strategy remain scarce.
HeartRhythm
MAY 22, 2024
The combined effect of left ventricular ejection fraction (LVEF) and atrial fibrillation (AF) on clinical outcomes in heart failure (HF) remains complex.
Journal of Cardiovascular Electrophysiology
FEBRUARY 13, 2024
Abstract Introduction Heart failure (HF) and atrial fibrillation (AF) frequently co-exist. Contemporary classification of HF categorizes it into HF with reduced ejection fraction (HFrEF), HF with mildly reduced ejection fraction (HFmrEF), and HF with preserved ejection fraction (HFpEF).
Journal of the American Heart Association
DECEMBER 29, 2023
BackgroundHeart failure with preserved ejection fraction ≥50% is prevalent with few evidence‐based therapies. Journal of the American Heart Association, Ahead of Print. These changes were paralleled by improvements in heart failure‐related quality of life (myPACE Minnesota Living with Heart Failure Questionnaire improved by 16.1
HeartRhythm
APRIL 30, 2024
The combined effect of Left Ventricular Ejection Fraction (LVEF) and the presence of Atrial Fibrillation (AF) on clinical outcomes in heart failure (HF) patients remains complex.
HeartRhythm
APRIL 30, 2024
Atrial fibrillation (AF) with comorbid heart failure with preserved ejection fraction (HFpEF) presents a significant management challenge. While the association between AF and heart failure with reduced ejection fraction is extensively studied, the correlation between AF and HFpEF remains less explored.
HeartRhythm
APRIL 30, 2024
A number of studies have examined the impact of atrial fibrillation (AF) ablation on outcomes in heart failure (HF) with reduced ejection (HFrEF) patients. In contrast, data from HF with preserved ejection fraction (HFpEF) patients is limited to small outcome studies and less robust meta-analyses.
HeartRhythm
APRIL 30, 2024
Previous studies have demonstrated significant morbidity and mortality in patients with heart failure (HF) with reduced ejection fraction (HFrEF), particularly with accompanying atrial fibrillation (AF).
HeartRhythm
APRIL 30, 2024
Overtime, various studies have reported variable mortality outcomes in heart failure with preserved ejection fraction (HFpEF) patients. It remains unclear to what extent atrial fibrillation (AF) creates increased mortality alone or in combination with either HFpEF or heart failure with reduced ejection fraction (HFrEF).
Circulation: Heart Failure
FEBRUARY 1, 2024
Background:NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels are variably elevated in heart failure with preserved ejection fraction (HFpEF), even in the presence of increased left ventricular filling pressures. Circulation: Heart Failure, Ahead of Print.
HeartRhythm
OCTOBER 18, 2024
The impact of comorbidity burden on outcomes of radiofrequency catheter ablation (RFCA) for atrial fibrillation (AF) in patients with heart failure and preserved ejection fraction (HFpEF) remains unclear.
Circulation: Heart Failure
SEPTEMBER 27, 2023
Multivariable linear regression models were used to assess associations of MMP-2 with measures of left ventricular and left atrial structure and function.RESULTS:Compared with the 3 lower quartiles, the highest MMP-2 quartile associated with greater risk of incident HF overall (adjusted hazard ratio, 1.48 [95% CI, 1.21–1.81]),
HeartRhythm
MARCH 31, 2025
Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) are conditions that frequently coexist and interact, creating a complex interplay with significant clinical implications.
The British Journal of Cardiology
AUGUST 21, 2024
Digoxin has been used in the management of chronic heart failure (HF) and atrial fibrillation (AF) for over 250 years. It is the only drug that combines an inotropic effect with a reduction in ventricular rate in AF. Therefore, in theory it should be an ideal treatment for HF, especially when there is co-existent AF.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content